and on friday make new high.
will come at 2PM news so expect close around 12-16 dollars
Blood products manufactured from donors receiving certain medications may contain significant levels of these medications. Transfusion of these products could result in adverse effects to certain recipients or to the developing fetus of a pregnant recipient.
Many factors should be considered when determining the potential harm of a drug present in a blood product. These include the drug's half-life, its mean and peak plasma concentration, the time that the drug was taken relative to the time of donation, the drug's long-term storage in the body, the dose that produced teratogenic effects in animals and humans, and the time during gestation at which the drug is most teratogenic relative to the time of transfusion. In addition, the blood product (and thus the level of drug) may be diluted if pooled or when transfused into the recipient's plasma volume. The level of drug may also be diluted or concentrated by the fractionation process.
remember ebola---they have treated with plasma.The US Food and Drug Administration (“FDA”) exercises rigorous control of plasma collection to assure its safety.
PlasmaTech utilizes its Optimized Plasma Process™ (OPP) – a patented method short two-step optimized salt precipitation process, in contrast to the highly denaturing Cohn process to extract a wide range of therapeutically useful biologic proteins from human blood plasma. OPP enables the production of unusually high yields of these proteins compared with the Cohn process. Plasma biologics primarily address indications arising from genetic deficiencies which are increasingly being identified by means of newly available rapid and low cost diagnostic genetic tests.
highly denaturing Cohn process to extract a wide range of therapeutically useful biologic proteins from human blood plasma.
i am very serious , this is the way i bought UTHR when she as 7 dollar
remember these guys know which co worth more then 1 B in future.
1.They have monopoly in the product which has 1 B dollar market
2.Expect 3 to 1 split when she goes to 16 dollar
3.Big demand for shares.
4.This company will make th deal from Aventis and Amgen in future.
5.NIH is ver keen on their compounds
you tell me that i am sick…..Blah blah!